bluebird bio, Inc. (0HOH.L)
USD 8.02
(1.01%)
USD 8.02
(1.01%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 619.16 Million USD | 11.58% |
| 2022 | 554.9 Million USD | -6.55% |
| 2021 | 593.79 Million USD | -66.66% |
| 2020 | 1.78 Billion USD | 3.12% |
| 2019 | 1.72 Billion USD | -22.98% |
| 2018 | 2.24 Billion USD | 18.01% |
| 2017 | 1.9 Billion USD | 69.98% |
| 2016 | 1.11 Billion USD | 11.55% |
| 2015 | 1 Billion USD | 80.04% |
| 2014 | 556.73 Million USD | 148.11% |
| 2013 | 224.39 Million USD | 223.69% |
| 2012 | 69.32 Million USD | 124.21% |
| 2011 | 30.91 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 631.48 Million USD | 1.99% |
| 2024 Q2 | 545.19 Million USD | -13.66% |
| 2023 Q4 | 619.16 Million USD | 0.9% |
| 2023 Q3 | 613.6 Million USD | -7.5% |
| 2023 Q2 | 663.39 Million USD | -4.24% |
| 2023 Q1 | 692.73 Million USD | 24.84% |
| 2023 FY | 619.16 Million USD | 11.58% |
| 2022 Q4 | 554.9 Million USD | 6.69% |
| 2022 Q2 | 573.59 Million USD | 16.8% |
| 2022 Q1 | 491.07 Million USD | -17.3% |
| 2022 FY | 554.9 Million USD | -6.55% |
| 2022 Q3 | 520.09 Million USD | -9.33% |
| 2021 Q1 | 1.63 Billion USD | -8.08% |
| 2021 Q2 | 1.45 Billion USD | -11.17% |
| 2021 FY | 593.79 Million USD | -66.66% |
| 2021 Q3 | 1.33 Billion USD | -7.89% |
| 2021 Q4 | 593.79 Million USD | -55.68% |
| 2020 Q4 | 1.78 Billion USD | -8.44% |
| 2020 Q3 | 1.94 Billion USD | -7.7% |
| 2020 Q1 | 1.52 Billion USD | -11.48% |
| 2020 Q2 | 2.1 Billion USD | 37.84% |
| 2020 FY | 1.78 Billion USD | 3.12% |
| 2019 Q2 | 2.02 Billion USD | -5.39% |
| 2019 FY | 1.72 Billion USD | -22.98% |
| 2019 Q4 | 1.72 Billion USD | -8.71% |
| 2019 Q3 | 1.89 Billion USD | -6.48% |
| 2019 Q1 | 2.13 Billion USD | -4.65% |
| 2018 Q1 | 1.86 Billion USD | -1.78% |
| 2018 FY | 2.24 Billion USD | 18.01% |
| 2018 Q4 | 2.24 Billion USD | -4.63% |
| 2018 Q3 | 2.35 Billion USD | 33.51% |
| 2018 Q2 | 1.76 Billion USD | -5.64% |
| 2017 Q1 | 1.07 Billion USD | -4.07% |
| 2017 Q2 | 1.45 Billion USD | 35.85% |
| 2017 FY | 1.9 Billion USD | 69.98% |
| 2017 Q4 | 1.9 Billion USD | 35.2% |
| 2017 Q3 | 1.4 Billion USD | -3.53% |
| 2016 Q3 | 918.26 Million USD | -2.49% |
| 2016 Q4 | 1.11 Billion USD | 21.77% |
| 2016 Q1 | 978.7 Million USD | -2.36% |
| 2016 Q2 | 941.66 Million USD | -3.78% |
| 2016 FY | 1.11 Billion USD | 11.55% |
| 2015 Q2 | 999.16 Million USD | 87.17% |
| 2015 Q3 | 1.01 Billion USD | 1.85% |
| 2015 Q4 | 1 Billion USD | -1.5% |
| 2015 Q1 | 533.81 Million USD | -4.12% |
| 2015 FY | 1 Billion USD | 80.04% |
| 2014 Q3 | 330.19 Million USD | 37.22% |
| 2014 Q1 | 209.51 Million USD | -6.63% |
| 2014 Q4 | 556.73 Million USD | 68.61% |
| 2014 Q2 | 240.62 Million USD | 14.85% |
| 2014 FY | 556.73 Million USD | 148.11% |
| 2013 Q2 | 234.54 Million USD | 70.63% |
| 2013 FY | 224.39 Million USD | 223.69% |
| 2013 Q4 | 224.39 Million USD | -1.7% |
| 2013 Q3 | 228.26 Million USD | -2.68% |
| 2013 Q1 | 137.45 Million USD | 98.29% |
| 2012 FY | 69.32 Million USD | 124.21% |
| 2012 Q4 | 69.32 Million USD | 0.0% |
| 2011 FY | 30.91 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| uniQure N.V. | 831.68 Million USD | 25.554% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 33.929% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 20.404% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -274.106% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -392.007% |
| Imunon, Inc. | 21.91 Million USD | -2724.888% |
| Editas Medicine, Inc. | 499.15 Million USD | -24.042% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 97.679% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 81.548% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 48.347% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 80.957% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 56.056% |
| Verastem, Inc. | 149.71 Million USD | -313.551% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 99.236% |
| Waters Corporation | 4.62 Billion USD | 86.618% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 99.373% |
| Biogen Inc. | 26.84 Billion USD | 97.694% |
| Nektar Therapeutics | 398.03 Million USD | -55.555% |
| Perrigo Company plc | 10.8 Billion USD | 94.272% |
| Dynavax Technologies Corporation | 997.09 Million USD | 37.904% |
| Illumina, Inc. | 10.11 Billion USD | 93.876% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -2089.984% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 20.656% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -178.267% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -842.55% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 90.95% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -274.523% |
| Evolus, Inc. | 188.99 Million USD | -227.602% |
| Adicet Bio, Inc. | 207.29 Million USD | -198.686% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -213.65% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 98.128% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -200.862% |
| FibroGen, Inc. | 423.52 Million USD | -46.191% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 94.247% |
| OPKO Health, Inc. | 2.01 Billion USD | 69.222% |
| Homology Medicines, Inc. | 47.05 Million USD | -1215.768% |
| Geron Corporation | 394.07 Million USD | -57.117% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 83.833% |
| Exelixis, Inc. | 2.94 Billion USD | 78.957% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -68.027% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -301.047% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 52.408% |
| Zoetis Inc. | 14.28 Billion USD | 95.666% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -5.257% |
| Abeona Therapeutics Inc. | 64 Million USD | -867.409% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 97.276% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -1006.652% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 79.293% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 81.034% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 0.379% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 64.278% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 40.99% |
| Insmed Incorporated | 1.32 Billion USD | 53.441% |
| TG Therapeutics, Inc. | 329.58 Million USD | -87.86% |
| Incyte Corporation | 6.78 Billion USD | 90.871% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | 66.256% |